Pharmaceutical companies in India are having to adapt to the World Health Organization’s International Nonproprietary Names programme, as Lucy Rana and Pooja Thakur explain.
Patents are portrayed and envisioned as the indispensable reward to compensate pharmaceutical firms for the large cost, risk and years of research that are put into drug discovery and development. However, this monopoly right comes with an expiration period. Brand loyalty towards a trademark of an off-patent drug can enable the manufacturer to enjoy indefinite benefits from a patent beyond its expiration.
However, brand loyalty and extensive marketing may lead to market monopolisation, a barrier that is very difficult for generic drug manufacturers to overcome. From a public health perspective this has numerous downsides.
For instance, it may lead to physicians prescribing brand-name drugs instead of generic substitutes. It can result not only in suppression of competition and reduction in consumer choice, but also in an increase in the price of drug to make up for the pharma company’s investment in aggressive brand promotion.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
Pharmaceuticals, branding, WHO, INN, Drugs and Cosmetics Act, India Trade Marks Act